Table 3.
Full Model* |
Reduced Model† |
|||
---|---|---|---|---|
HR (95% CI) | P Value | HR (95% CI) | P Value | |
Age | ||||
Unit change | 1.01 (0.99–1.03) | 0.379 | ||
Hemoglobin, g/dl | ||||
Unit change | 0.83 (0.71–0.98) | 0.025 | 0.78 (0.67–0.91) | 0.001 |
Time from consultation to bronchoscopy, d | ||||
Unit change | 1.00 (0.99–1.01) | 0.689 | ||
Gender | ||||
Male | ||||
Female | 0.66 (0.37–1.17) | 0.152 | ||
Heart | ||||
No | ||||
Yes | 0.89 (0.47–1.70) | 0.724 | ||
Anticoagulant therapy | ||||
No | ||||
Yes | 3.07 (0.97–9.69) | 0.056 | ||
ECOG PS | ||||
PS 0 | ||||
PS 1 | 2.00 (0.54–7.36) | 0.298 | ||
PS 2 | 3.61 (0.88–14.86) | 0.075 | ||
PS 3 | 6.28 (1.28–30.78) | 0.023 | ||
Stage | ||||
Early | ||||
Advanced | 9.53 (2.09–43.41) | 0.004 | 10.80 (2.53 –46.08) | 0.001 |
Active bleeding and endobrochial lesion | ||||
no-AB/no-EBL | ||||
no-AB/EBL | 1.58 (0.57–4.40) | 0.383 | 1.29 (0.53 –3.16) | 0.572 |
AB/no- EBL | 3.24 (1.16–9.04) | 0.025 | 2.40 (0.98 –5.85) | 0.055 |
AB/EBL | 2.80 (1.37–5.72) | 0.005 | 3.20 (1.74 –5.89) | <0.001 |
Resolved in 48 h | ||||
No | ||||
Yes | 0.66 (0.29–1.46) | 0.302 | 0.43 (0.22–0.84) | 0.014 |
Blood transfusion | 0.84 (0.28–2.54) | 0.759 | ||
No | ||||
Yes |
P < 0.10 in the univariate analysis.
P < 0.05 in the univariate analysis.